Navigation and service

Phase I Clinical Trials Approved for Alzheimer’s Drug Candidate

Jülich, 20 March 2018 – In what represents a first milestone on the road to application, the drug candidate for the treatment of Alzheimer’s disease, PRI-002, has received approval for phase I clinical trials. At an independent clinic, the potential Alzheimer’s drug will initially be assessed under strict requirements to see whether it is safe for humans. The drug was developed at Forschungszentrum Jülich and Heinrich Heine University Düsseldorf. In September 2017, Priavoid GmbH was founded as a spin-off of Forschungszentrum Jülich with the aim of launching the drug on market.

More (in German)







Dear visitor,

To make our website suit your needs even more and to give it a more appealing design, we would like you to answer a few short questions.

Answering these questions will take approx. 10 min.

Start now Close window

Thank you for your support!


In case you have already taken part in our survey or in case you have no time to take part now, you can simply close the window by clicking "close".

If you have any questions on the survey, please do not hesitate to contact:


Your Team at Forschungszentrum Jülich


Note: Forschungszentrum Jülich works with the market research institute SKOPOS to anonymously conduct and analyze the survey. SKOPOS complies with the statutory requirements on data protection as well as with the regulations of ADM (Arbeitskreis Deutscher Markt- und Sozialforschungsinstitute e.V.) and ESOMAR (Europäische Gesellschaft für Meinungs- und Marketingforschung). Your data will not be forwarded to third parties.